Sensus Healthcare (NASDAQ:SRTS) had its target price boosted by Maxim Group from $7.50 to $9.00 in a report released on Friday. The brokerage currently has a “buy” rating on the stock. Maxim Group’s price objective suggests a potential upside of 63.04% from the company’s current price.
Separately, TheStreet cut shares of Sensus Healthcare from a “c-” rating to a “d” rating in a report on Thursday, January 25th.
Shares of Sensus Healthcare (SRTS) traded down $0.06 during midday trading on Friday, reaching $5.52. 26,503 shares of the company were exchanged, compared to its average volume of 10,244. The stock has a market cap of $73.51 and a PE ratio of -22.00. Sensus Healthcare has a one year low of $3.38 and a one year high of $6.25.
COPYRIGHT VIOLATION WARNING: “Maxim Group Boosts Sensus Healthcare (SRTS) Price Target to $9.00” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/02/maxim-group-boosts-sensus-healthcare-srts-price-target-to-9-00.html.
About Sensus Healthcare
Sensus Healthcare, Inc, formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy.
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.